Neil M. Iyengar, MD

Final takeaways from a discussion on best practices treating HR+/HER2- metastatic breast cancer with CDK4/6 inhibitors and PI3K therapies based on data presented at ESMO 2021.

Variables that impact how breast oncologists should sequence therapies when managing patients with HR+/HER2- metastatic breast cancer.

Strategies to help breast oncologists counsel patients on metabolic conditions when treating patients with HR+/HER2- metastatic breast cancer with PI3K inhibitors.

Breast oncologists share pearls regarding best practices treating patients with HR+/HER2- metastatic breast cancer with PI3K inhibitor therapy and mitigating treatment-related adverse events.

Considerations for treating patients with HR+/HER2- metastatic breast cancer with alpelisib, a PI3K inhibitor, following frontline treatment with a CDK4/6 inhibitor.

The impact of recent data presented at ESMO 2021 in terms of selecting an appropriate CDK4/6 inhibitor as first-line treatment of HR+/HER2- metastatic breast cancer.

Similarities and differences between available CDK4/6 inhibitors used to treat HR+/HER2- metastatic breast cancer.

Clinical pearls regarding best practices preventing and/or managing common treatment-related adverse events associated with CDK4/6 inhibitors used to treat HR+/HER2- metastatic breast cancer.

Insight on how to best sequence therapy for patients with HR+/HER2- advanced breast cancer based on updated data from the MONALEESA trials.

Considerations regarding the association of quality of life with overall survival in patients with HR+/HER2- advanced breast cancer treated with ribociclib and endocrine therapy.

A panel of breast oncologists review first-line treatment options for patients with HR+/HER2- metastatic breast cancer, commenting on treatment advances utilizing CKD4/6 inhibitors.

Dr. Neil Iyengar highlights variables that factor into treatment decisions for patients with HR+/HER2- metastatic breast cancer.

Kicking off a discussion regarding recent data presented at ESMO 2021, a panel of breast oncologists share their preferences for conducting molecular testing to identify mutations such as PIK3CA that can help determine how to treat patients with HR+/HER2- metastatic breast cancer.